Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell t... Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.4 | 2.7397260274 | 14.6 | 15.43 | 13.62 | 580323 | 14.52713116 | CS |
4 | -0.15 | -0.990099009901 | 15.15 | 16.17 | 12.31 | 788463 | 14.24946379 | CS |
12 | -3.75 | -20 | 18.75 | 20.75 | 12.25 | 1231681 | 15.3859641 | CS |
26 | 10.86 | 262.31884058 | 4.14 | 23.4 | 3.52 | 2094923 | 14.17801254 | CS |
52 | 10.95 | 270.37037037 | 4.05 | 23.4 | 3.52 | 1222667 | 12.97481644 | CS |
156 | 11.83 | 373.186119874 | 3.17 | 23.4 | 2.68 | 516358 | 11.14146363 | CS |
260 | 13.43 | 855.414012739 | 1.57 | 23.4 | 0.88 | 926395 | 7.86767473 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.